0000000000292147
AUTHOR
Marc Jennewein
UTSW Small Animal Positron Emission Imager
A Small Animal Imager (SAI) for PET has been designed, built, tested in phantoms, and applied to investigations in mice and rats. The device uses principles based on gamma-ray induced scintillation in crossed fiber optic detectors connected to Position Sensitive Photomultiplier Tubes (PSPMT). Each detector consists of an epoxied stack of 28 layers of 135 round 1 mm BCF-10 scintillating plastic fibers. The overlap region forms a 13.5times13.5times2.8 cm3 detector volume. Scintillating light from the fibers is detected by two (X and Y directions) Hamamatsu R-2486 PSPMTs with 16 anode wires in each of two orthogonal directions. A centroid-finding algorithm gives the position of a light cluster…
Preliminary assessment of the imaging capability of the YAP–(S)PET small animal scanner in neuroscience
The new and fully engineered version of the YAP–(S)PET small animal scanner has been tested at the University of Mainz for preliminary assessment of its imaging capability for studies related to neuropharmacology and psychiatry. The main feature of the scanner is the capability to combine PET and SPECT techniques. It allows the development of new and interesting protocols for the investigation of many biological phenomena, more effectively than with PET or SPECT modalities alone. The scanner is made up of four detector heads, each one composed of a 4 � 4c m 2 of YAlO3:Ce (or YAP:Ce) matrix, and has a field of view (FOV) of 4 cm axially � 4c m + transaxially. In PET mode, the volume resoluti…
Separation and purification of no-carrier-added arsenic from bulk amounts of germanium for use in radiopharmaceutical labelling
AbstractRadioarsenic labelled radiopharmaceuticals could add special features to molecular imaging with positron emission tomography (PET). For example the long physical half-lives of72As (T1/2=26 h) and74As (T1/2=17.8 d) in conjunction with their high positron branching rates of 88% and 29%, respectively, allow the investigation of slow physiological or metabolical processes, like the enrichment and biodistribution of monoclonal antibodies in tumour tissue or the characterization of stem cell trafficking. A method for separation and purification of no-carrier-added (nca) arsenic from irradiated metallic germanium targets based on distillation and anion exchange is developed. It finally con…
Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine.
Abstract Purpose: We recently reported that anionic phospholipids, principally phosphatidylserine, become exposed on the external surface of vascular endothelial cells in tumors, probably in response to oxidative stresses present in the tumor microenvironment. In the present study, we tested the hypothesis that a chimeric monoclonal antibody that binds phosphatidylserine could be labeled with radioactive arsenic isotopes and used for molecular imaging of solid tumors in rats. Experimental Design: Bavituximab was labeled with 74As (β+, T1/2 17.8 days) or 77As (β−, T1/2 1.6 days) using a novel procedure. The radionuclides of arsenic were selected because their long half-lives are consistent w…
A no-carrier-added 72Se/72As radionuclide generator based on distillation
Abstract Arsenic-72 is a positron emitting isotope with promising properties for syntheses of 72As-labelled radiopharmaceuticals for future application in positron emission tomography. This work describes the radiochemical separation of no-carrier-added 72Se from cyclotron irradiated germanium targets and the development of a 72Se/72As radionuclide generator, avoiding the addition of any selenium carrier. Using a vertical quartz tube device, no-carrier-added 72As is nearly quantitatively released from various chloride salt solutions containing 72Se within 10 min at a temperature of 100 °C in an HCl gas flow. The kinetics of the 72Se/72As isotope generator has been studied in relation to tem…
A new method for radiochemical separation of arsenic from irradiated germanium oxide.
Abstract Radioarsenic labelled radiopharmaceuticals could be a valuable asset to Positron Emission Tomography (PET). In particular, the long half-lives of 72 As ( T 1/2 =26 h) and 74 As ( T 1/2 =17.8 d) allow to investigate slow physiological or metabolical processes, like the enrichment and distribution of antibodies in tumor tissue. This work describes the direct production of no-carrier-added (nca) arsenic isotopes *As, with *=71, 72, 73, 74 or 77, the reaction to [*As]AsI 3 and its radiochemical separation from the irradiated solid germanium oxide via polystyrene-based solid-phase extraction. The germanium oxide target, irradiated at a cyclotron or a nuclear reactor, is dissolved in con…
Projection and Pinhole-Based Data Acquisition for Small-Animal SPECT Using Storage Phosphor Technology
Three-dimensional Single Photon Emission Computed Tomography (SPECT) can provide high-resolution insight into biomolecular distribution and pharmacokinetics. However, instrument availability and distribution is limited at present,and imaging times can be considerable. To evaluate the large array of novel agents which are becoming available,we find that storage phosphor-based in vivo imaging can provide an important,rapid-throughput transition from the traditional ex vivo sacrifice/gamma counting and autoradiography to full-time course SPECT.
A new method for the labelling of proteins with radioactive arsenic isotopes
Abstract Radioarsenic labelled radiopharmaceuticals could be a valuable asset to positron emission tomography. In particular, the long half-lives of 72As ( T 1 / 2 = 26 h ) and 74As ( T 1 / 2 = 17.8 d ) allow to investigate slow physiological or metabolical processes, like the enrichment and distribution of monoclonal antibodies (mab) in tumour tissue. In this work, a new method for the labelling of proteins with various radioactive arsenic isotopes was developed. For this purpose, two proteins, namely a chimeric IgG3 monoclonal antibody, ch3G4, directed against anionic phospholipids, and Rituxan (Rituximab), were labelled as a proof of principle with no-carrier-added radioarsenic isotopes…
A no-carrier-added72Se/72As radionuclide generator based on solid phase extraction
Summary72As-labelled radiopharmaceuticals could be a valuable resource for Positron Emission Tomography (PET). In particular, the long half-life of72As (T1/2= 26 h) facilitates the observation of long-term physiological or metabolic processes, such as the enrichment and distribution of antibodies in tumor tissue. This work describes the primary radiochemical separation of no-carrier-added (nca)72Se from cyclotron irradiated germanium targets and the development of a polystyrene type solid-phase extraction based72Se/72As radionuclide generator, avoiding the addition of any selenium carrier. The irradiated germanium target is dissolved in HFconcand selenium is reduced with hydrazine dihydroch…